Literature DB >> 26436447

Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.

Federico Salomone1, Justyna Godos2, Shira Zelber-Sagi3,4.   

Abstract

Non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD), is emerging as a main health problem in industrialized countries. Lifestyle modifications are effective in the treatment of NAFLD; however, the long-term compliance is low. Therefore, several pharmacological treatments have been proposed but none has shown significant efficacy or long-term safety. Natural polyphenols are a heterogeneous class of polyphenolic compounds contained in vegetables, which are being proposed for the treatment of different metabolic disorders. Although the beneficial effect of these compounds has traditionally related to their antioxidant properties, they also exert several beneficial effects on hepatic and extra-hepatic glucose and lipid homeostasis. Furthermore, natural polyphenols exert antifibrogenic and antitumoural effects in animal models, which appear relevant from a clinical point of view because of the association of NASH with cirrhosis and hepatocellular carcinoma. Several polyphenols, such anthocyanins, curcumin and resveratrol and those present in coffee, tea, soy are available in the diet and their consumption can be proposed as part of a healthy diet for the treatment of NAFLD. Other phenolic compounds, such as silymarin, are commonly consumed worldwide as nutraceuticals or food supplements. Natural antioxidants are reported to have beneficial effects in preclinical models of NAFLD and in pilot clinical trials, and thus need clinical evaluation. In this review, we summarize the existing evidence regarding the potential role of natural antioxidants in the treatment of NAFLD and examine possible future clinical applications.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NASH; fibrosis; nutraceuticals; oxidative stress; polyphenols

Mesh:

Substances:

Year:  2015        PMID: 26436447     DOI: 10.1111/liv.12975

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  67 in total

1.  Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress.

Authors:  H Malhi; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-09       Impact factor: 8.171

2.  Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Francesco Luzza; Luigi Boccuto; Antonino De Lorenzo
Journal:  J Transl Int Med       Date:  2017-09-30

3.  Higher serum carotenoids associated with improvement of non-alcoholic fatty liver disease in adults: a prospective study.

Authors:  Mian-Li Xiao; Geng-Dong Chen; Fang-Fang Zeng; Rui Qiu; Wen-Qi Shi; Jie-Sheng Lin; Yi Cao; Hua-Bin Li; Wen-Hua Ling; Yu-Ming Chen
Journal:  Eur J Nutr       Date:  2018-03-29       Impact factor: 5.614

4.  Effects of Ganoderma Lucidum shell-broken spore on oxidative stress of the rabbit urinary bladder using an in vivo model of ischemia/reperfusion.

Authors:  Robert M Levin; Li Xia; Wu Wei; Catherine Schuler; Robert E Leggett; Alpha D-Y Lin
Journal:  Mol Cell Biochem       Date:  2017-05-08       Impact factor: 3.396

5.  Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice.

Authors:  Xinwei Li; Zhen Shi; Yiwei Zhu; Taiyu Shen; Heyuan Wang; Guanghou Shui; Juan J Loor; Zhiyuan Fang; Meng Chen; Xinghui Wang; Zhicheng Peng; Yuxiang Song; Zhe Wang; Xiliang Du; Guowen Liu
Journal:  Br J Pharmacol       Date:  2020-06-14       Impact factor: 8.739

6.  Chlorogenic acid alleviates autophagy and insulin resistance by suppressing JNK pathway in a rat model of nonalcoholic fatty liver disease.

Authors:  Hua Yan; Yan-Qiong Gao; Ying Zhang; Huan Wang; Gui-Sheng Liu; Jian-Yuan Lei
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

Review 7.  The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.

Authors:  Maria Del Ben; Licia Polimeni; Francesco Baratta; Daniele Pastori; Francesco Angelico
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

8.  A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis.

Authors:  Ling Li; Guo-Fang Zhang; Kwangwon Lee; Rocio Lopez; Stephen F Previs; Belinda Willard; Arthur McCullough; Takhar Kasumov
Journal:  Free Radic Biol Med       Date:  2016-03-30       Impact factor: 7.376

Review 9.  Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment.

Authors:  Mariia Zadorozhna; Sante Di Gioia; Massimo Conese; Domenica Mangieri
Journal:  Mol Biol Rep       Date:  2020-02-10       Impact factor: 2.316

Review 10.  Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases.

Authors:  Gregori Casals; Meritxell Perramón; Eudald Casals; Irene Portolés; Guillermo Fernández-Varo; Manuel Morales-Ruiz; Victor Puntes; Wladimiro Jiménez
Journal:  Antioxidants (Basel)       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.